Pharma Medical Affairs AI Data

Medical affairs AI data, verified by medical and regulatory experts.

Acumen supplies data from MSLs, medical information specialists and regulatory writers. We use it to teach and test the LLMs your medical affairs team runs internally.

Request a sample datasetSchedule a conversation

What is medical affairs AI data?

Medical affairs AI data is content written, graded or reviewed by MSLs, medical information specialists, medical writers and regulatory experts to train and test LLMs used inside pharma. It includes reference answers to medical information requests, graded literature summaries, scored model outputs and reviewed regulatory drafts. Acumen delivers it with reviewer credentials and an audit trail on every item.

The challenge

Why is medical affairs slow to adopt GenAI?

GenAI is moving into medical information content, KOL insight generation, medical-legal review support and training tools (IQVIA 2026; IntuitionLabs 2026). Strategy& modeled $130–370M a year in operating margin uplift from use cases that touch medical affairs, for a hypothetical pharma company with $30B in operating profit. The value is real. So is the risk. An unbalanced answer to an HCP is a compliance problem, and fixing the code won't solve it.

Consilience Strategy (2026) finds medical affairs slower to adopt AI because regulation and accuracy demands are higher. Internal LLM platforms are now standard at the top 50 pharma companies. The platform isn't the bottleneck. The data that teaches and tests it is. Generic models and generic labelers don't know what a standard response document is, or when a summary overstates a subgroup analysis.

Acumen is built to close that gap.

Expert-led data

Scientific judgment as the backbone, not an afterthought.

The questions medical affairs leads ask before an internal model goes live:

  1. How do we evaluate a medical information chatbot before it answers an HCP?
  2. Who grades the outputs, and would our medical reviewers trust their judgment?
  3. Does every answer stay scientifically balanced and non-promotional?
  4. Does it cite the right studies and summarize them accurately?
  5. Can the data and the testing sit inside our SOPs and audit trail?
Expertise

From generic labelers to medical affairs professionals.

A generalist can check grammar. A generalist can't tell when a response drops the safety data, leans on a post hoc analysis or reads like promotion. Those misses go straight into the model.

We match every task to credential-checked MSLs, medical information specialists, medical writers or regulatory writers, by therapeutic area.

This enables something generic labeling cannot: an audit trail your reviewers can follow.

De-risking

How do you de-risk an internal medical affairs LLM?

Health AI evaluation has moved from multiple-choice exams to expert rubrics. OpenAI's HealthBench (May 2025) graded models against criteria written by 262 physicians. HealthBench Professional (2026) now scores writing, documentation and medical research tasks, with rubrics adjudicated by three or more physicians. Medical affairs needs the same discipline, written by its own experts. We give teams four ways to get it:

Reference answers to medical information requests

Experts write gold-standard responses to unsolicited HCP questions, built to the standard of your SRDs.

Rubrics and graded outputs

MSLs and medical information specialists score model answers for accuracy, balance, citations and tone. They also compare responses side by side to produce preference data.

Graded literature summaries

Medical writers check model summaries against the source paper: population, endpoints, effect sizes, limitations and citations.

Reviewed regulatory drafts

Regulatory writers mark up model-drafted sections. Each draft and its expert revision become training and evaluation data.

Deployment moves from cautious pilots to a de-risked, expert-led process.

Continuous data

From one dataset to a continuous data pipeline.

Labels change. New data reads out. SRDs get revised after every congress season. A model tested once falls behind. The questions are constant:

  1. Does the model reflect the current label and the latest SRD revisions?
  2. Has it picked up new publications, and does it summarize them fairly?
  3. Did this release introduce promotional drift or unbalanced answers?
  4. Which therapeutic areas and request types still lack coverage?

Acumen answers them with expert data delivered on a recurring cadence, release after release.

The reality

Why don't ad hoc review and generic labeling hold up?

  1. MSLs grade outputs off the side of their desks, between field work and inquiries
  2. Reviews live in spreadsheets and email threads, not an audit trail
  3. Generic labelers can't tell a balanced response from a promotional one
  4. No shared rubric, so two reviewers score the same answer differently
  5. Hard to show QA, compliance or an auditor how the model was tested

Review is easy to start. Documented expert judgment is not.

Expert data, on demand

How does Acumen deliver medical affairs data you can trust?

  1. Credential-checked MSLs, medical information, medical writing and regulatory experts, matched by therapeutic area
  2. Rubrics built with your team and mapped to your SRDs and SOPs
  3. Multi-reviewer adjudication on every item, with agreement scores
  4. Full provenance: reviewer role, therapeutic area, rubric version and how disagreements were resolved
  5. Training-ready formats (JSONL, CSV, custom schemas), piloted in weeks and scaled on demand

From scattered spot-checks → expert data built for production.

Compare

Acumen vs. crowdsourced vs. in-house review for medical affairs AI

Acumen expert dataCrowdsourced annotationIn-house review
Who reviewsMSLs, medical information specialists, medical and regulatory writersGeneralist workforceYour MSLs and medical information team, part-time
Therapeutic area coverageMatched per taskLimitedLimited to your portfolio staff
Scientific balance and promotional riskScored in every rubricRarely assessedStrong judgment, inconsistent scoring
Quality controlShared rubric, multi-review adjudicationSpot checksVaries by reviewer
Audit trailReviewer, rubric version and resolution per itemMinimalSpreadsheets and email
CapacityScales on demandScales, but not for specialist workCompetes with field and inquiry workload
Fits SOPs and QA reviewYes, documentedRarelyPartly
Trust

Data you can defend, from QA review to audit.

Regulators increasingly treat data as evidence. FDA's January 2025 draft guidance on AI-enabled device software asks sponsors to describe how data was collected, cleaned and processed, and how test data was kept independent. Most medical affairs tools aren't devices. The direction is still clear. EU AI Act obligations for general-purpose AI models applied from August 2025, with transparency obligations from August 2026.

Every Acumen item carries its provenance: who reviewed it, their role and therapeutic area, and how disagreements were resolved. We keep evaluation sets separate from training data. We package it all with documentation your QA, compliance and medical-legal teams can review.

The shift.

In the age of AI, models are abundant. Advantage comes from the data behind them. In medical affairs, that data has to come from the people who answer HCP questions, review the literature and write for regulators.

Acumen is the expert data layer for training, evaluating and trusting AI in medical affairs, medical information and regulatory writing.

THE ENGAGEMENT

Pilot dataset.
Expert-verified.

Scoping call: request types, therapeutic areas and SOPs

Rubric design with your medical affairs leads

Pilot dataset: expert-reviewed items with a reviewer agreement report

Scale to recurring delivery

Request a sample dataset

Medical affairs AI data: frequently asked questions

What is medical affairs AI data?

Medical affairs AI data is content written, graded or reviewed by MSLs, medical information specialists, medical writers and regulatory experts to train and test internal pharma LLMs. It includes reference answers to medical information requests, scoring rubrics, graded literature summaries and reviewed regulatory drafts. Acumen delivers it matched by therapeutic area, adjudicated by multiple reviewers and documented item by item.

How do we evaluate a medical information chatbot?

Build an evaluation set from representative medical information requests, each with an expert reference answer and a rubric for accuracy, scientific balance, citations and tone. Score every model release against it. A 2025 literature survey on HealthBench found that strong average scores can mask dangerous weaknesses, so track worst-case answers, not just the mean.

Can MSLs and medical writers grade model outputs?

Yes, and they should. They know what a good response to an HCP looks like. We supply credential-checked MSLs, medical information specialists and medical writers, matched by therapeutic area, who grade outputs against a shared rubric. Your team reviews a calibration set first, so our scoring matches your standards before volume starts.

How do you keep responses scientifically balanced and non-promotional?

We score balance instead of assuming it. Rubrics check whether a response answers the question asked, presents efficacy and safety together, states study limitations, cites the evidence and avoids promotional language. Reviewers flag drift item by item. We also build adversarial test sets that try to push the model into claims it shouldn't make.

Can this support our SOPs and audit trail?

Yes. Every item records who reviewed it, their role and therapeutic area, the rubric version and how disagreements were resolved. We align rubrics and workflows with your SOPs during scoping and deliver documentation your QA and compliance teams can review. Evaluation sets stay separate from training data, so test results remain independent.

Do you support regulatory writing models?

Yes. Regulatory writers review model-drafted documents, marking factual errors, gaps and unsupported statements. Each draft and its expert revision become training data, and scored drafts become an evaluation set. FDA's January 2025 draft guidance on AI-enabled device software shows where expectations are heading: describe how data was collected and processed, and keep test data independent.

Which experts and therapeutic areas do you cover?

We source MSLs, medical information specialists, medical writers and regulatory writers, and recruit for narrower areas on request. Your standard response documents and internal materials stay confidential and go only to the reviewers assigned to your project.

How fast can we get a pilot dataset?

Data arrives as JSONL, CSV or a custom schema matched to your pipeline, with reviewer role, therapeutic area and agreement on every item. Production volumes follow on a recurring cadence.

Last updated November 2026

Related pages

Medical model evaluationHealthcare AI red teamingPharma commercial data